tan, beware this kind of people, don't do water fish for them, they simply words for fishing.

hahaha....see you past comments already know you are the king of blow beef!!!

blow beef no need costing de ^^

from 3rd Jan till today already got 1,400mil share turnover, almost 45% of total share 3,100mil, but the price still in strong support, I believe mostly share have in institution hand now.

HLIB Research Report, 18th Jan 2022

We initiate coverage on DNeX with a highly convicted BUY recommendation and
TP of RM1.35/share based on sum-of-parts (SOP) valuation. We peg its
technology segment to a CY23F P/E of 25x, which is at a slight discount to its
global peers weighted average forward P/E of 26x. While we understand that
SilTerra is a relatively small player in this space and has a relatively promising
technology vs. its listed global peers, we believe that valuation is justified as we
are expecting SilTerra to grow faster than peers, with a growth of 28% (vs. a
weighted average of 23% for its global peers). At about 14x FY23F earnings in its
entirety, we believe that DNeX is a compelling case given its strong foothold in
both the semiconductor and energy spaces.

有赚钱就卖了，现在已经不是疫苗的趋势，马来西亚接种疫苗已经有大概3千五百万剂，而且下来会以Az和Prizer为主，Pharma只代装sinovac，其他的都会直接进口，除非pharma有研发出自己的疫苗，将可能还有机会！

哇！你的记性厉害，还记得哟，我还在股市，没有在这里了啦！

突破再突破，恭喜大家巨赚啦(^o^)v

嘻嘻嘻。。医药股趋势不在Liao，只是少赚点罢了，没关系啦,fpi, revenue再接再厉(^o^)